Iovance Biotherapeutics Inc Stock News

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options

IOVA Investors with Losses Encouraged to Contact Hagens Berman SAN FRANCISCO, CA / ACCESS Newswire / June 12, 2025 / A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically.

LOS ANGELES , June 12, 2025 /PRNewswire/ -- Glancy Prongay & Murray LLP announces that investors with losses have opportunity to lead the securities fraud class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or the "Company") (NASDAQ: IOVA). IF YOU SUFFERED A LOSS ON YOUR IOVANCE INVESTMENTS, CLICK HERE BEFORE JULY 14, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE SECURI...

SAN FRANCISCO, June 11, 2025 (GLOBE NEWSWIRE) -- A year ago, Bay Area biotech firm Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) was riding high on the promise of its newly approved cell therapy, Amtagvi. Today, the mood has shifted dramatically. On May 16, 2025, UBS analysts reportedly slashed their rating on Iovance shares from Buy to Neutral and issued a stark price target cut—from $17 to jus...

BENSALEM, Pa. , June 10, 2025 /PRNewswire/ -- The Law Offices of Howard G.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Iovance To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Iovance between August 8, 2024 and May 8, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1...

SAN CARLOS, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following conference:

LOS ANGELES , June 9, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Iovance Biotherapeutics, Inc. ("Iovance" or "the Company") (NASDAQ: IOVA) for violations of the federal securities laws. Shareholders who purchased the Company's securities between May 9, 2024 and May 8, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before ...